Genelux (GNLX) Expected to Announce Earnings on Thursday

Genelux (NASDAQ:GNLX) is projected to release its results before the market opens on Thursday, November 13th. Analysts expect Genelux to post earnings of ($0.23) per share for the quarter.

Genelux (NASDAQ:GNLX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Trading Up 8.7%

GNLX opened at $5.89 on Tuesday. The company’s 50 day moving average is $5.23 and its 200-day moving average is $3.80. Genelux has a 1-year low of $1.99 and a 1-year high of $8.53. The company has a market cap of $224.11 million, a P/E ratio of -6.69 and a beta of -0.10.

Hedge Funds Weigh In On Genelux

A number of hedge funds have recently made changes to their positions in GNLX. Osaic Holdings Inc. boosted its holdings in Genelux by 1,911.4% in the second quarter. Osaic Holdings Inc. now owns 105,016 shares of the company’s stock valued at $301,000 after acquiring an additional 99,795 shares during the last quarter. Raymond James Financial Inc. raised its holdings in Genelux by 22.6% during the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after purchasing an additional 5,333 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Genelux in the 2nd quarter worth approximately $92,000. Geode Capital Management LLC boosted its stake in shares of Genelux by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock valued at $915,000 after purchasing an additional 5,596 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Genelux during the first quarter worth $190,000. 37.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GNLX has been the topic of a number of research analyst reports. Lake Street Capital started coverage on shares of Genelux in a research report on Tuesday, October 21st. They issued a “buy” rating and a $16.00 target price on the stock. HC Wainwright reissued a “buy” rating on shares of Genelux in a report on Wednesday, July 23rd. Maxim Group set a $20.00 target price on Genelux in a report on Tuesday, October 21st. Loop Capital set a $16.00 target price on Genelux in a research report on Tuesday, October 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.